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ROP in the developing world
Retinopathy of prematurity (ROP) is a growing problem in South 
Africa (SA), as it is in many parts of the developing world. The 
so-called ‘third epidemic’ of ROP is caused by a combination of high 
preterm birth rates, relatively good infant survival and inadequate 
oxygen monitoring in neonatal facilities.[1] Increasing ROP incidence 
(due to these factors) has been identified particularly in Latin 
America and Eastern Europe. SA is generally accepted as having 
similar challenges in the care of preterm neonates, both in the private 
and public sectors.
ROP is a fibrovascular complication of poorly vascularised 
premature retinal tissue. It is mediated by vascular endothelial 
growth factor (VEGF) and insulin-like growth factor, among 
others. The main complication of untreated advanced ROP is 
retinal detachment, leading to blindness in one or both eyes, with 
potentially major impacts on the health, education and economic 
potential of the affected individual. ROP occurs exclusively in 
premature infants, and the SA guidelines recommend screening 
of all neonates born prior to 32 weeks’ gestation and all preterm 
neonates weighing <1 500 g.[2] 
Conventional treatment
Treatment of advanced ROP has traditionally involved laser 
photocoagulation of the avascular peripheral retinal tissue, thus 
reducing the stimulus to retinal neovascularisation as well as fibrosis 
and scarring. Unfortunately, laser treatment is not without its risks 
– it is associated with high myopia (often noted many years after the 
laser treatment), visual field constriction and retinal detachment. The 
general anaesthesia (GA) typically required for conventional laser 
treatment carries its own attendant risks in the premature infant. 
And then, even with optimal laser treatment, visual outcomes are 
less than ideal.  In the ‘ETROP’[3] study, application of retinal laser for 
prethreshold disease showed better outcomes than cryotherapy, but 
the final visual outcomes were still less than ideal – 25% of treated 
eyes having vision worse than 20/200 and 65% having vision not good 
enough for a driver’s licence.[3]
Anti-VEGF treatment
With this background in mind, it is not surprising that anti-VEGF 
agents have become so popular in recent years. A single intravitreal 
injection of anti-VEGF agent, performed under local anaesthesia 
alone (i.e. without sedation or GA), effectively reverses the ROP 
neovascularisation process in most cases.
The most commonly used agent, bevacizumab (Avastin, 
Genentech, USA) is a monoclonal anti-VEGF antibody. It has been 
shown to be better than conventional laser treatment for posterior 
(zone I) disease, and equal to laser for so-called ‘threshold’ disease. [4] 
The article by Kana et al.[5] demonstrates the effectiveness of 
bevacizumab in a local SA state hospital setting with an admirable 
success rate of 95% in patients with ‘threshold disease’ (2 failures 
progressing to retinal detachment out of 43 treated eyes). 
The main drivers behind the increasing use of bevacizumab 
internationally are cost and ease of use. Both are mentioned in the 
Kana et al.[5] article. In settings where funding is limited, where 
experienced ophthalmologists are in short supply or where neonatal 
theatre and high-care facilities are scarce, it makes sense that an 
option that allows safe, effective, rapid treatment at the bedside is 
gaining popularity.
Current management of ROP in SA
Currently, ~50% of ophthalmologists involved in ROP management 
in SA report making use of bevacizumab to treat ROP in their 
practice. A growing number (up to 30%) make use of anti-VEGF 
agents as their primary treatment modality (email survey presented 
at World Society of Paediatric Ophthalmology & Strabismus Meeting, 
2015). The reasons given for use of bevacizumab included ‘ease of 
use’ and ‘efficacy’ as well as ‘cost’. Several treating units have no laser 
device available, and therefore would not be able to treat infants with 
ROP were it not for the availability of bevacizumab.
Each year, ~24 000 infants are born in SA at risk of ROP (roughly 
1 million live births per year, of whom 2.4% are preterm <32 weeks). 
Each of these infants should ideally have retinal screening performed 
2 or 3 times to rule out ROP. As the number of preterm infants born 
and surviving in SA continues to rise, the burden of ROP screening 
and treatment can be expected to follow suit, and the use of anti-
VEGF agents to treat threshold ROP is likely to gather momentum.
Safety concerns
Intravitreal anti-VEGF treatment is, however, not without potential 
problems. The treatment is relatively new and there are still questions 
about its safety profile. Normal angiogenesis is a key component in 
the development of the eye as well as other vital systems (lung and 
brain especially). 
Intravitreal anti-VEGF causes regression of the ROP process, but 
also causes slowing or stalling of the peripheral retinal vascularisation, 
leaving a permanent avascular zone in some treated infants, with 
serious concerns that this may lead to later retinal detachment.[6] Also, 
the slow resolution mandates prolonged weekly surveillance to ensure 
that there are no late ROP recurrences (up to 60 weeks in some cases). 
Underlining fears about systemic safety, bevacizumab has been 
detected in the serum of both infants and adults after intraocular 
injection,[7] leading to ongoing debate around appropriate dosage and the 
best anti-VEGF agent. The dose used by Kana et al.[5] (0.625 mg) is the 
same as used by most authors in the current literature, although some 
have recommended a lower dose of 0.25 mg.[8,9] A lower dose would be 
expected to reduce systemic complications at the expense of a higher 
risk of recurrence. Conversely, a larger molecule size would be expected 
to reduce transit out of the eye and therefore also theoretically reduce 
systemic interactions. This helps to explain why another anti-VEGF agent 
(ranibizumab; Lucentis, Genentech & Novartis, USA) with a smaller 
molecule has not found favour among treating ophthalmologists.
Finally, the risk of endophthalmitis – caused by organisms 
introduced into the eye at the time of transconjunctival/transscleral 
injection – is a major concern. This has been shown clearly in the 
use of anti-VEGF agents to treat macular degeneration, diabetic 
retinopathy and other forms of macular oedema in adults. Meticulous 
sterile technique and medication preparation is required to keep this 
risk as low as possible.[10]
Medico-legal implications
It is unlikely that anti-VEGF agents will become licensed in SA for 
ROP treatment in the near future (since the number of cases involved 
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is insufficient). Therefore, as with any new and developing area, using 
a so-called ‘off-label’ medication should be approached with caution. 
There is a growing body of evidence that anti-VEGF treatment is 
both effective and safe, but practitioners entering into this arena are 
advised to carefully document, among other things, available options, 
informed consent, dosage used, safety precautions employed and 
follow-up arrangements. 
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